|
Thrombophilia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Protein C deficiency is a heritable thrombophilia caused by numerous different genetic alterations in the protein C (PROC) gene.
|
31821907 |
2020 |
|
Thrombophilia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Analysis of PROC and PROS1 single nucleotide polymorphisms in a thrombophilia family.
|
31295762 |
2019 |
|
Thrombophilia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The heterozygous mutation locus c.565C>T on the PROC gene is associated with thrombophilia.
|
30210609 |
2018 |
|
Thrombophilia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Subsequently, it was demonstrated that a mutation in a single clotting factor, FV, showed resistance to activated protein C. Since activated protein C is supposed to downregulate aFV and aFVIII, their persistence in the circulation gives origin to a hypercoagulable state.
|
29063359 |
2018 |
|
Thrombophilia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Plasma hypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis.
|
27421039 |
2017 |
|
Thrombophilia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Impairment of the anticoagulant protein C system occurs during endotoxemia and contributes to sepsis-associated hypercoagulability.
|
29285085 |
2017 |
|
Thrombophilia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Conclusions FVBonn induces hypercoagulability via a combination of increased activation/procoagulant activity, decreased susceptibility to APC-mediated inactivation, and slightly reduced APC cofactor activity.
|
27090446 |
2016 |
|
Thrombophilia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Whether APC dysfunction occurs in other Asian countries is an important aspect of mapping thrombophilia among Asians.
|
23301217 |
2013 |
|
Thrombophilia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Thrombin generation assays sensitive to the APC- and TFPI-cofactor activities of protein S revealed similar hypercoagulable states in type I and type III protein S-deficient plasma.
|
20378562 |
2010 |
|
Thrombophilia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Thrombin generation assays sensitive to the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S revealed similar hypercoagulable states in type I and type III protein S-deficient plasma.
|
20421270 |
2010 |
|
Thrombophilia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
One of the most common hereditary thrombophilias is the factor V Leiden mutation, which is identified with a screening assay for activated protein C (APC) resistance and confirmed by DNA analysis.
|
18854273 |
2008 |
|
Thrombophilia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Activated protein C resistence (APCR) is a genetically determined cause of thrombophilia and DIC development.
|
16496494 |
2006 |
|
Thrombophilia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Activated protein C (aPC) resistance is a recognized hypercoagulable phenotype that is associated with increased risk for thrombosis in multiple clinical settings.
|
15562039 |
2004 |
|
Thrombophilia
|
0.200 |
AlteredExpression
|
disease |
LHGDN |
Cigarette smoke dose-dependent hypercoagulability due to acquired activated protein C deficiency could contribute to the increased risk of thrombosis in smokers.
|
12482406 |
2003 |
|
Thrombophilia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Recently, a poor anticoagulant response to activated protein C (APC), due to a mutation of factor V (FV Leiden), has been identified as the most frequent hereditary disorder associated with venous thrombophilia.
|
12221665 |
2002 |
|
Thrombophilia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
This mutation, defined as factor VLEIDEN, results in activated protein C (APC) resistance and is the most common genetic risk factor for familial thrombophilia.
|
11914653 |
2002 |
|
Thrombophilia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis.
|
11776306 |
2001 |
|
Thrombophilia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Factor V is an important blood coagulation factor, the procoagulatory activity of which is inhibited by activated protein C. The factor V Leiden mutation is due to a single base-pair change (G1691A), which alters the initial cleavage site for activated protein C. The impaired degradation of factor V by activated protein C yields a hypercoagulable state that confers a lifelong increased risk of thrombosis in heterozygous and homozygous individuals.
|
11342806 |
2001 |
|
Thrombophilia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A resistance to the anticoagulant activity of activated protein C (APC), most frequently due to a point mutation in the Factor V gene (the Leiden mutation), represents the most common genetic cause of thrombophilia.
|
10874575 |
2000 |
|
Thrombophilia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The cause of the BCS still being unknown, in October 1996 we performed extensive laboratory investigations concerning states of thrombophilia and found moderately elevated IgG anticardiolipin antibodies (19.7 U/ml) and a resistance against activated protein C caused by heterozygosity for a point mutation of the factor V gene (1691G-->A; factor V Leiden).
|
10378363 |
1999 |
|
Thrombophilia
|
0.200 |
Biomarker
|
disease |
BEFREE |
We compare results of factor V DNA analysis with three different clotting-based assays designed to detect activated protein C (APC) resistance (APCR), using samples from 958 patients undergoing assessment for thrombophilia.
|
10492912 |
1999 |
|
Thrombophilia
|
0.200 |
Biomarker
|
disease |
BEFREE |
In an attempt to investigate the prevalence of hypercoagulable states in patients with venous leg ulcers, we performed a prospective case-control study for the presence of coagulation defects in such patients, including resistance to activated protein C (APC), factor V Leiden mutation and a newly described mutation in factor II.
|
10468797 |
1999 |
|
Thrombophilia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
To evaluate the role of inherited thrombophilia in the development of central venous line (CVL)-related thrombosis, the following parameters were determined in 77 pediatric-oncologic patients with CVL: activated protein C (APC)-ratio, factor V (FV) G1691A and prothrombin G20210A mutation, protein C, protein S, antithrombin, coagulation factor XII, lipoprotein (a) and homocysteine.
|
10650856 |
1999 |
|
Thrombophilia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Inherited resistance to activated protein C (APC) has been recently recognized as a novel cause underlying venous thrombophilia.
|
9763354 |
1998 |
|
Thrombophilia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The factor V Leiden gene mutation decreases the sensitivity of factor V to the anticoagulant activity of activated protein C, and has been shown to be the most common inherited defect associated with a hypercoagulable state.
|
9625586 |
1998 |